Navigation Links
Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors

OXFORD, England and SAN JOSE, California, January 15, 2014 /PRNewswire/ --

Oxford BioTherapeutics, an international biotechnology company developing antibody-drug conjugates for cancer, today announced the appointment of Thomas C Reynolds MD, PhD to its Board of Directors. Dr Reynolds has over 20 years' development experience gained in the biotechnology industry, most recently as Chief Medical Officer at Seattle Genetics.

"I am delighted to welcome Tom at this transformative time for Oxford BioTherapeutics, as the company completes its transition into a fully-fledged oncology product development business," said Bryan Morton, Chairman of Oxford BioTherapeutics. "Dr Reynolds' experience in the oncology field will prove invaluable as we progress our pipeline into the clinic, and in particular his expertise in bringing antibody-drug conjugates to market having led the development and approval of ADCETRIS at Seattle Genetics."

Commenting on his appointment, Thomas C Reynolds MD, PhD, said, "I am highly impressed with Oxford BioTherapeutics' cancer targeting technology, which has continued to mature since my tenure at Seattle Genetics. I am delighted to be able to contribute to the development of the company's exciting antibody-based oncology products."

About Thomas C Reynolds MD, PhD

Dr Reynolds has held a number of senior development roles during his career of over 20 years in the biotechnology industry. Most recently he was Chief Medical Officer at Seattle Genetics, where he had direct oversight of the development and approval of the company's antibody-drug conjugate, ADCETRIS. Prior to this, he was Vice President for Medical Affairs at Zymogenetics, having held the role of Senior Medical Director. Previously, he held a number of senior roles at Targeted Genetics Corporation, culminating in the position of Vice President, Clinical Affairs. He began his industry career at Somatix Therapy Corporation as a Research Scientist. Dr Reynolds gained his MD at Stanford University, where he subsequently conducted postdoctoral research. He also holds a PhD in Biophysics from Stanford University, and a degree in Chemistry from Dartmouth College.

About Oxford BioTherapeutics

Oxford BioTherapeutics is developing a range of antibody-drug conjugates for cancer, based on its OGAP® oncology targeting technology. The OGAP® system incorporates one of the world's largest proprietary proteomic databases, with data on 7,500 cancer cell proteins providing unique, highly-qualified therapeutic targets. The company has established collaborations with leading antibody and cancer toxin technology companies, including Seattle Genetics, to build an in-house pipeline of antibody-drug conjugates (ADCs) against a number of these novel targets. In 2012, Oxford BioTherapeutics entered a strategic agreement to accelerate the development of its ADCs, with partner Menarini providing clinical and manufacturing expertise and investment of up to $1 billion in exchange for commercial rights to the treatments outside the US and Japan.

Oxford BioTherapeutics is based in Oxford, UK and San Jose, CA, and has a strong management team with significant experience of developing antibody-based therapies. The company has completed a number of funding rounds, and is supported by a syndicate of specialist venture capital investors. For more information please visit

Dr Christian Rohlff
Oxford BioTherapeutics

David Dible / Sita Shah
Citigate Dewe Rogerson

SOURCE Oxford BioTherapeutics
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Oxford University Press to publish BioScience journal starting in 2014
2. Oxford BioMedica Announces Update from ARVO 2013
3. Oxford BioTherapeutics and Boehringer Ingelheim Enter Collaboration to Discover Novel Antibody Targets in Cancer
4. Oxford Performance Materials and Biomet Microfixation Join Forces
5. Oxford University Hospitals NHS Trust and the Bodleian Libraries Select ClinicalKey
6. Oxford Finance Completes $271.4 Million Securitization Transaction
7. Oxford Finance and Silicon Valley Bank Provide $15 Million Senior Credit Facility to NanoString Technologies
8. Oxford Finance Provides $15 Million Senior Secured Credit Facility to Private Equity Backed Healthcare Services Company
9. Oxford BioTherapeutics Appoints C. Glenn Begley as a Senior Clinical Advisor and Non-executive Director
10. Agilis Biotherapeutics and Intrexon to Pursue Transformative Therapies for Rare Genetic Disease
11. Northwest Biotherapeutics to Present at the Oppenheimer 24th Annual Healthcare Conference On December 10, 2013
Post Your Comments:
(Date:11/24/2015)... LUMPUR, Malaysia , Nov. 24, 2015 /PRNewswire/ ... global contract research organisation (CRO) market. The trend ... result in lower margins but higher volume share ... increased capacity and scale, however, margins in the ... Research Organisation (CRO) Market ( ), ...
(Date:11/24/2015)... Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will be presenting at ... on Wednesday, December 2 at 9:30 a.m. ET/6:30 a.m. PT ... provide a corporate overview. th Annual Oppenheimer Healthcare ... ET/10:00 a.m. PT . Jim Mazzola , vice president ... --> th Annual Oppenheimer Healthcare Conference in ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... ... event of the year and one of the premier annual events for pharmaceutical ... ran from 8–11 November 2015, where ISPE hosted the largest number of attendees ...
(Date:11/24/2015)... PUNE, India , November 24, 2015 ... to a new market research report "Oligonucleotide Synthesis Market ... Equipment), Application (PCR, Gene Synthesis, Diagnostic, DNA, RNAi), End-User ... to 2020", published by MarketsandMarkets, the market is expected ... 1,078.1 Million in 2015, at a CAGR of 10.1% ...
Breaking Biology Technology:
(Date:11/16/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), ... announced expansion of its TDDI product portfolio with ... and display driver integration (TDDI) solutions designed to ... TDDI products add to the previously-announced TD4300 ... resolution), and TD4322 (FHD resolution) solutions. All four ...
(Date:11/11/2015)... --  MedNet Solutions , an innovative SaaS-based eClinical technology company ... to announce that it will be a Sponsor of the ... be held November 17-19 in Hamburg , ... iMedNet , MedNet,s easy-to-use, proven and affordable ... been able to deliver time and cost savings of up ...
(Date:11/9/2015)... JOSE, Calif. , Nov. 9, 2015  Synaptics ... human interface solutions, today announced broader entry into the ... vehicle-specific solutions that match the pace of consumer electronics ... and biometric sensors are ideal for the automotive industry ... vehicle. Europe , ...
Breaking Biology News(10 mins):